BrainsGate

Minimally Invasive Treatment for Central Nervous System Diseases

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
BrainsGate
02/07/2022
NeuroModulation
Medical devices | Medical equipment
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Invasive Neuromodulation
01/01/2000
"11-50"

BrainsGate is a medical device company that develops therapies for patients suffering from central nervous system diseases, with a focus on the treatment of acute ischemic stroke. The company’s platform technology involves electrical stimulation of the sphenopalatine ganglion, a nerve center known to increase cerebral blood flow.



Building on its technology, BrainsGate has developed the Ischemic Stroke System (ISS), in which a miniature electrode is implanted in the roof of the mouth in a minimally invasive bedside procedure performed under local anesthesia and comparable to a dental treatment.



In 2008, BrainsGate completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011, the company completed a 300-patient RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients.



BrainsGate is currently running the ImpACT-24b, a multinational, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.